Trials / Completed
CompletedNCT00080340
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (planned)
- Sponsor
- Telik · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 (Telcyta) HCl for Injection | |
| DRUG | gefitinib (Iressa) |
Timeline
- Completion
- 2005-05-01
- First posted
- 2004-03-30
- Last updated
- 2008-01-15
Locations
338 sites across 8 countries: United States, Argentina, Australia, Brazil, Chile, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT00080340. Inclusion in this directory is not an endorsement.